Late luteal phase administration of RU486 for three successive cycles does not disrupt bleeding patterns or ovulation

Horacio B. Croxatto, Ana Maria Salvatierra, Carmen Romero, Irving M. Spitz

Resultado de la investigación: Article

24 Citas (Scopus)

Resumen

RU486, a 19-nor steroid, binds with high affinity to the receptors for progesterone and glucocorticoids, blocking the actions of these hormones on their target tissues. We conducted studies to determine whether RU486 administered at the end of the luteal phase would disturb the menstrual rhythm, ovulation, or hormonal parameters in the treatment and posttreatment cycles. The first study was done in six surgically sterilized women during two consecutive cycles. RU486 [17βQ-hydroxy-11β-(4-dimethylaminophenyl)17α-(1-propynyl)estra-4, 9-dien-3-one; 100 mg/day] was given for 4 consecutive days, commencing on days 23-27 of the first cycle. Menstrual bleeding occurred by the second day of RU486 administration in all women and was indistinguishable from their usual bleeding pattern. The onset of this bleeding was advanced by RU486 administration, since it entailed shortening of the luteal phase with prolongation of the following follicular phase. Serum LH, FSH, estradiol, and progesterone levels were normal in five of the six women in both the treatment and posttreatment cycles. The second study was conducted in 10 women who were not exposed to the risk of pregnancy. RU486 (100 mg/day) was given for 4 consecutive days, commencing 4 days before their expected menses for 3 successive cycles, preceded and followed by 2 placebo-treated cycles. Bleeding patterns were indistinguishable during the RU486 and placebo cycles. Late luteal phase administration of RU486 consistently produced menstrual bleeding within 1–3 days of drug administration. Daily early morning urinary LH excretion in 6 women and estrone glucuronide and pregnanediol glucuronide excretion in 5 women during both placebo and RU486 cycles were consistent with luteinization, suggesting ovulation and appropriate corpus luteum function. We conclude that RU486 has no major effect on menstrual cycle events if given at the time of the natural progesterone withdrawal that occurs before menses in nonpregnant women.

Idioma originalEnglish
Páginas (desde-hasta)1272-1277
Número de páginas6
PublicaciónJournal of Clinical Endocrinology and Metabolism
Volumen65
N.º6
DOI
EstadoPublished - 1987

Huella dactilar

Luteal Phase
Ovulation
Hemorrhage
Glucuronides
Progesterone
Pregnanediol
Menstruation
Placebos
Estrone
Glucocorticoid Receptors
Progesterone Receptors
Estradiol
Luteinization
Steroids
Hormones
Tissue
Follicular Phase
Corpus Luteum
Menstrual Cycle
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Citar esto

@article{f11c6025243040cc8e63e18abfa8c31b,
title = "Late luteal phase administration of RU486 for three successive cycles does not disrupt bleeding patterns or ovulation",
abstract = "RU486, a 19-nor steroid, binds with high affinity to the receptors for progesterone and glucocorticoids, blocking the actions of these hormones on their target tissues. We conducted studies to determine whether RU486 administered at the end of the luteal phase would disturb the menstrual rhythm, ovulation, or hormonal parameters in the treatment and posttreatment cycles. The first study was done in six surgically sterilized women during two consecutive cycles. RU486 [17βQ-hydroxy-11β-(4-dimethylaminophenyl)17α-(1-propynyl)estra-4, 9-dien-3-one; 100 mg/day] was given for 4 consecutive days, commencing on days 23-27 of the first cycle. Menstrual bleeding occurred by the second day of RU486 administration in all women and was indistinguishable from their usual bleeding pattern. The onset of this bleeding was advanced by RU486 administration, since it entailed shortening of the luteal phase with prolongation of the following follicular phase. Serum LH, FSH, estradiol, and progesterone levels were normal in five of the six women in both the treatment and posttreatment cycles. The second study was conducted in 10 women who were not exposed to the risk of pregnancy. RU486 (100 mg/day) was given for 4 consecutive days, commencing 4 days before their expected menses for 3 successive cycles, preceded and followed by 2 placebo-treated cycles. Bleeding patterns were indistinguishable during the RU486 and placebo cycles. Late luteal phase administration of RU486 consistently produced menstrual bleeding within 1–3 days of drug administration. Daily early morning urinary LH excretion in 6 women and estrone glucuronide and pregnanediol glucuronide excretion in 5 women during both placebo and RU486 cycles were consistent with luteinization, suggesting ovulation and appropriate corpus luteum function. We conclude that RU486 has no major effect on menstrual cycle events if given at the time of the natural progesterone withdrawal that occurs before menses in nonpregnant women.",
author = "Croxatto, {Horacio B.} and Salvatierra, {Ana Maria} and Carmen Romero and Spitz, {Irving M.}",
year = "1987",
doi = "10.1210/jcem-65-6-1272",
language = "English",
volume = "65",
pages = "1272--1277",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "6",

}

Late luteal phase administration of RU486 for three successive cycles does not disrupt bleeding patterns or ovulation. / Croxatto, Horacio B.; Salvatierra, Ana Maria; Romero, Carmen; Spitz, Irving M.

En: Journal of Clinical Endocrinology and Metabolism, Vol. 65, N.º 6, 1987, p. 1272-1277.

Resultado de la investigación: Article

TY - JOUR

T1 - Late luteal phase administration of RU486 for three successive cycles does not disrupt bleeding patterns or ovulation

AU - Croxatto, Horacio B.

AU - Salvatierra, Ana Maria

AU - Romero, Carmen

AU - Spitz, Irving M.

PY - 1987

Y1 - 1987

N2 - RU486, a 19-nor steroid, binds with high affinity to the receptors for progesterone and glucocorticoids, blocking the actions of these hormones on their target tissues. We conducted studies to determine whether RU486 administered at the end of the luteal phase would disturb the menstrual rhythm, ovulation, or hormonal parameters in the treatment and posttreatment cycles. The first study was done in six surgically sterilized women during two consecutive cycles. RU486 [17βQ-hydroxy-11β-(4-dimethylaminophenyl)17α-(1-propynyl)estra-4, 9-dien-3-one; 100 mg/day] was given for 4 consecutive days, commencing on days 23-27 of the first cycle. Menstrual bleeding occurred by the second day of RU486 administration in all women and was indistinguishable from their usual bleeding pattern. The onset of this bleeding was advanced by RU486 administration, since it entailed shortening of the luteal phase with prolongation of the following follicular phase. Serum LH, FSH, estradiol, and progesterone levels were normal in five of the six women in both the treatment and posttreatment cycles. The second study was conducted in 10 women who were not exposed to the risk of pregnancy. RU486 (100 mg/day) was given for 4 consecutive days, commencing 4 days before their expected menses for 3 successive cycles, preceded and followed by 2 placebo-treated cycles. Bleeding patterns were indistinguishable during the RU486 and placebo cycles. Late luteal phase administration of RU486 consistently produced menstrual bleeding within 1–3 days of drug administration. Daily early morning urinary LH excretion in 6 women and estrone glucuronide and pregnanediol glucuronide excretion in 5 women during both placebo and RU486 cycles were consistent with luteinization, suggesting ovulation and appropriate corpus luteum function. We conclude that RU486 has no major effect on menstrual cycle events if given at the time of the natural progesterone withdrawal that occurs before menses in nonpregnant women.

AB - RU486, a 19-nor steroid, binds with high affinity to the receptors for progesterone and glucocorticoids, blocking the actions of these hormones on their target tissues. We conducted studies to determine whether RU486 administered at the end of the luteal phase would disturb the menstrual rhythm, ovulation, or hormonal parameters in the treatment and posttreatment cycles. The first study was done in six surgically sterilized women during two consecutive cycles. RU486 [17βQ-hydroxy-11β-(4-dimethylaminophenyl)17α-(1-propynyl)estra-4, 9-dien-3-one; 100 mg/day] was given for 4 consecutive days, commencing on days 23-27 of the first cycle. Menstrual bleeding occurred by the second day of RU486 administration in all women and was indistinguishable from their usual bleeding pattern. The onset of this bleeding was advanced by RU486 administration, since it entailed shortening of the luteal phase with prolongation of the following follicular phase. Serum LH, FSH, estradiol, and progesterone levels were normal in five of the six women in both the treatment and posttreatment cycles. The second study was conducted in 10 women who were not exposed to the risk of pregnancy. RU486 (100 mg/day) was given for 4 consecutive days, commencing 4 days before their expected menses for 3 successive cycles, preceded and followed by 2 placebo-treated cycles. Bleeding patterns were indistinguishable during the RU486 and placebo cycles. Late luteal phase administration of RU486 consistently produced menstrual bleeding within 1–3 days of drug administration. Daily early morning urinary LH excretion in 6 women and estrone glucuronide and pregnanediol glucuronide excretion in 5 women during both placebo and RU486 cycles were consistent with luteinization, suggesting ovulation and appropriate corpus luteum function. We conclude that RU486 has no major effect on menstrual cycle events if given at the time of the natural progesterone withdrawal that occurs before menses in nonpregnant women.

UR - http://www.scopus.com/inward/record.url?scp=0023605879&partnerID=8YFLogxK

U2 - 10.1210/jcem-65-6-1272

DO - 10.1210/jcem-65-6-1272

M3 - Article

C2 - 3119656

AN - SCOPUS:0023605879

VL - 65

SP - 1272

EP - 1277

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 6

ER -